Volume 9 Supplement 3

Proceedings of the 2007 and 2008 Drug Discovery for Neurodegeneration Conference


Edited by Howard Fillit and Antony Horton

The conference and the publication of these proceedings were supported by a conference grant: U13-AG031125 from the National Institute of Aging and the National Institute for Neurological Disorders and Stroke. Additional support was provided by CoMentis, Inc; Pfizer, Inc.; Biogen Idec and Boehringer Ingelheim Pharmaceuticals, Inc.

2007 and 2008 Drug Discovery for Neurodegeneration Conference. Go to conference site.

New York, USA. 5-6 February 2007

Washington, DC, USA. 4-5 February 2008

  1. Research

    NAP and D-SAL: neuroprotection against the β amyloid peptide (1–42)

    NAP (Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln, single amino acid letter code, NAPVSIPQ), an eight amino acid neuroprotective peptide derived from activity-dependent neuroprotective protein (ADNP), exhibits some structu...

    Illana Gozes, Inna Divinski and Inbar Piltzer

    BMC Neuroscience 2008 9(Suppl 3):S3

    Published on: 10 December 2008

  2. Review

    Intranasal administration of acetylcholinesterase inhibitors

    This short review outlines the rationale, challenges, and opportunities for intranasal acetylcholinesterases, in particular galantamine. An in vitro screening model facilitated the development of a therapeuticall...

    Henry R Costantino, Alexis Kays Leonard, Gordon Brandt, Paul H Johnson and Steven C Quay

    BMC Neuroscience 2008 9(Suppl 3):S6

    Published on: 10 December 2008

  3. Review

    Requirements for a lead compound to become a clinical candidate

    A drug candidate suitable for clinical testing is expected to bind selectively to the receptor site on the target, to elicit the desired functional response of the target molecule, and to have adequate bioavai...

    Franz F Hefti

    BMC Neuroscience 2008 9(Suppl 3):S7

    Published on: 10 December 2008